Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 434

1.

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study.

Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K, Nordaby M, Kleine E, Bis B, Gerstenfeld EP; RE-CIRCUIT® investigators.

Europace. 2019 Apr 14. pii: euz057. doi: 10.1093/europace/euz057. [Epub ahead of print]

PMID:
30982849
2.

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.

Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L, Morillo CA, Abozguia K, Grimaldi M, Rauer H, Reimitz PE, Smolnik R, Mönninghoff C, Kautzner J.

Eur Heart J. 2019 Apr 11. pii: ehz190. doi: 10.1093/eurheartj/ehz190. [Epub ahead of print]

PMID:
30976787
3.

How to maximize QRS narrowing.

Braun O, Vamos M, Erath JW, Hohnloser SH.

Herzschrittmacherther Elektrophysiol. 2019 Apr 8. doi: 10.1007/s00399-019-0616-0. [Epub ahead of print]

PMID:
30963248
4.

Effectiveness of single- vs. dual-coil implantable defibrillator leads: An observational analysis from the SIMPLE study.

Neuzner J, Hohnloser SH, Kutyifa V, Glikson M, Dietze T, Mabo P, Vinolas X, Kautzner J, O'Hara G, Lawo T, Brachmann J, VanErven L, Gadler F, Appl U, Wang J, Connolly SJ, Healey JS; Shockless IMPLant Evaluation (SIMPLE) investigators.

J Cardiovasc Electrophysiol. 2019 Apr 4. doi: 10.1111/jce.13943. [Epub ahead of print]

PMID:
30945798
5.

[Management of oral anticoagulation related intracerebral hemorrhage].

Sembill JA, Kuramatsu JB, Hohnloser SH, Huttner HB.

Herz. 2019 Apr 2. doi: 10.1007/s00059-019-4802-y. [Epub ahead of print] German.

PMID:
30941474
6.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Mar 1;212:13-22. doi: 10.1016/j.ahj.2019.02.006. [Epub ahead of print]

PMID:
30928824
7.

Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.

Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R.

Thromb Haemost. 2019 Mar 21. doi: 10.1055/s-0039-1683422. [Epub ahead of print]

PMID:
30900223
8.

Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.

Hohnloser SH, Basic E, Nabauer M.

Thromb Haemost. 2019 Mar 21. doi: 10.1055/s-0039-1683428. [Epub ahead of print]

PMID:
30900220
9.

EHRA White Paper: knowledge gaps in arrhythmia management-status 2019.

Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo JC, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H; ESC Scientific Document Group .

Europace. 2019 Mar 18. pii: euz055. doi: 10.1093/europace/euz055. [Epub ahead of print]

PMID:
30882143
10.

Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.

Alak A, Hohnloser SH, Fräßdorf M, Reilly P, Ezekowitz M, Healey JS, Brueckmann M, Yusuf S, Connolly SJ.

Europace. 2019 Mar 8. pii: euz021. doi: 10.1093/europace/euz021. [Epub ahead of print]

PMID:
30848783
11.

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.

Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP.

Eur Heart J. 2019 Feb 21. pii: ehz059. doi: 10.1093/eurheartj/ehz059. [Epub ahead of print]

PMID:
30793734
12.

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.

Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators.

J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y.

PMID:
30790160
13.

Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial.

Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD.

Circulation. 2019 Feb 18. doi: 10.1161/CIRCULATIONAHA.118.037955. [Epub ahead of print]

PMID:
30773022
14.

Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database.

Hohnloser SH, Basic E, Nabauer M.

Clin Res Cardiol. 2019 Feb 15. doi: 10.1007/s00392-019-01437-7. [Epub ahead of print]

PMID:
30771066
15.

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study.

Hohnloser SH, Calkins H, Willems S, Verma A, Schilling R, Okumura K, Nordaby M, Kleine E, Biss B, Gerstenfeld EP; RE-CIRCUIT® investigators.

J Interv Card Electrophysiol. 2019 Feb 13. doi: 10.1007/s10840-019-00518-x. [Epub ahead of print]

PMID:
30758702
16.

Efficacy and safety of transvenous lead extraction in 108 consecutive patients: a single-centre experience.

Monsefi N, Waraich HS, Vamos M, Erath J, Sirat S, Moritz A, Hohnloser SH.

Interact Cardiovasc Thorac Surg. 2018 Dec 28. doi: 10.1093/icvts/ivy351. [Epub ahead of print]

PMID:
30597017
17.

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update.

Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH.

Am J Cardiol. 2019 Jan 1;123(1):69-74. doi: 10.1016/j.amjcard.2018.09.036. Epub 2018 Oct 4.

PMID:
30539748
18.

Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.

Cardoso R, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Nordaby M, Brouwer MA, Calkins H.

Clin Cardiol. 2019 Jan;42(1):198-205. doi: 10.1002/clc.23120. Epub 2018 Dec 7. Review.

19.

Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial.

Bogdan S, Glikson M, Connolly SJ, Wang J, Hohnloser SH, Appl U, Neuzener J, Mabo P, Vinolas X, Gadler F, van Erven L, Kautzner J, Meeks B, Pogue J, Healey JS.

Heart Rhythm. 2019 Jan;16(1):83-90. doi: 10.1016/j.hrthm.2018.07.030. Epub 2018 Jul 29.

PMID:
30063996
20.

A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.

Camm AJ, Dorian P, Hohnloser SH, Kowey PR, Tyl B, Ni Y, Vandzhura V, Maison-Blanche P, de Melis M, Sanders P.

Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):21-28. doi: 10.1093/ehjcvp/pvy022.

PMID:
30052825

Supplemental Content

Loading ...
Support Center